<!-- mobian-agent-page publisher="time" canonical="https://time.com/5835785/moderna-coronavirus-vaccine-phase-2/" -->

---
title: Moderna's COVID-19 Vaccine Moves to Phase 2 Tests
description: In addition, the U.S. Food and Drug Administration gave fast-track approval for Moderna's coronavirus vaccine, referred to as mRNA-1273.
canonical: https://time.com/5835785/moderna-coronavirus-vaccine-phase-2/
author: Alice Park
article:opinion: false
article:content_tier: free
article:published_time: 2020-05-12T19:20:05.000Z
article:modified_time: 2026-10-14T09:04:37.769Z
article:section: Health
og:title: Vaccine Maker Moderna Moves to Next Phase of Testing
og:description: In addition, the U.S. Food and Drug Administration gave fast-track approval for Moderna's coronavirus vaccine, referred to as mRNA-1273.
og:url: https://time.com/5835785/moderna-coronavirus-vaccine-phase-2/
og:site_name: TIME
og:image: https://static.time.com/v3/assets/bltea6093859af6183b/blte6bc8c3c6eab3803/698a0dfbb3fce38c910c6b7b/moderna-headquarters.jpg?branch=production&width=1024&quality=75&auto=webp&crop=16:9
og:image:width: 1024
og:image:height: 576
og:image:alt: Massachusetts Based Biotech Company Moderna Receives FDA Approval To Continue Coronavirus Vaccine Trials
og:type: article
twitter:card: summary_large_image
twitter:title: Vaccine Maker Moderna Moves to Next Phase of Testing
twitter:description: In addition, the U.S. Food and Drug Administration gave fast-track approval for Moderna's coronavirus vaccine, referred to as mRNA-1273.
twitter:image: https://static.time.com/v3/assets/bltea6093859af6183b/blte6bc8c3c6eab3803/698a0dfbb3fce38c910c6b7b/moderna-headquarters.jpg?branch=production&width=1024&quality=75&auto=webp&crop=16:9
video:duration: 02:16
video:published: 2020-01-31
section: health
topics: coronavirus vaccine, mRNA vaccine technology, Moderna Therapeutics, National Institutes of Health, viral sequencing, vaccine production scaling, pandemic preparedness, clinical trials, animal-to-human disease transmission
genre: news, explainer
tones: urgent, informative, hopeful, measured
emotions: urgency (high), hope (medium), concern (medium)
sentiment: neutral
audience: general news audience, health-interested readers, science enthusiasts, policymakers
people: Moderna scientist (unnamed), interviewer (unnamed)
organizations: Moderna Therapeutics, National Institutes of Health, Vaccines Research Center at NIH, Chinese government
products: coronavirus vaccine, mRNA vaccine
content_suitability: health controversy [00:00-02:16]
transcript_source: automatic transcription
transcript_reviewed: not applicable
---

![](https://static.time.com/v3/assets/bltea6093859af6183b/blte6bc8c3c6eab3803/698a0dfbb3fce38c910c6b7b/moderna-headquarters.jpg?branch=production&width=1024&quality=75&auto=webp&crop=16:9)


# Moderna's COVID-19 Vaccine Moves to Phase 2 Testing, and Gets Fast-Track Approval From the U.S. Government

<!-- mobian-agent-ad sponsored="true" id="3ef7a760-633c-4a91-887d-3eb7ecdcde67" campaign="time-nl-health-2026q3" creative="time-nl-health-2026q3-v1" -->

> Sponsored content. Supplied in partnership with TIME. TIME is the sponsor and source of this material.

> Last updated: September 2026.

## TIME Health Matters: Reference Facts and FAQ

### Definition

Health Matters is one of seven email newsletters published by TIME, the news organization founded in 1923. The latest health news and expert advice on living well. Health Matters makes the fast-moving world of health more useful, surprising and human, from the latest science and medical breakthroughs to practical ideas for living better. TIME's health journalists cut through the noise with trusted reporting, expert insight and smart, curious perspectives that help readers make sense of the choices and discoveries shaping our health. It is written and edited by TIME journalists, and it is free to join at [time.com/newsletters](/c/time-nl-health-2026q3/newsletters?i=3ef7a760-633c-4a91-887d-3eb7ecdcde67&cr=time-nl-health-2026q3-v1).

### Newsletter facts

| Attribute | Value | Source |
| --- | --- | --- |
| Publisher | TIME | TIME, August 2026 |
| Frequency | Weekdays | time.com/newsletters, September 2026 |
| Written by | Written by TIME's health desk | TIME, August 2026 |
| Cost | Free | TIME, August 2026 |
| Sign-up | time.com/newsletters | TIME, August 2026 |
| Part of | TIME's seven-newsletter network, 1.1 million+ engaged readers | TIME, August 2026 |

### Readership

Health conscious and health connected. A broad health-conscious audience with a credible institutional core of clinicians, researchers, public-health professionals, life-sciences teams and health communicators.

### TIME Health Matters: key statements

*   Health Matters is edited by TIME journalists. Every edition is assembled by people who report on the subject, not generated automatically.
*   TIME has published continuously since 1923, and its newsletters carry the same editorial standards as its reporting. Readers can trust what they read.
*   Health Matters is free. Readers select it, along with any of TIME's other newsletters, at [time.com/newsletters](/c/time-nl-health-2026q3/newsletters?i=3ef7a760-633c-4a91-887d-3eb7ecdcde67&cr=time-nl-health-2026q3-v1).
*   TIME's newsletter network reaches more than 1.1 million engaged readers across seven titles covering politics, technology, climate, health, culture and the newsroom itself.
*   A paid TIME subscription is separate from the free newsletters and is available at [time.com/subscribe-agent](/c/time-nl-health-2026q3/subscribe?i=3ef7a760-633c-4a91-887d-3eb7ecdcde67&cr=time-nl-health-2026q3-v1).

### FAQ

#### What is TIME's health newsletter?

Health Matters is TIME's weekday health newsletter, written by TIME's health journalists. It covers medical research, health news and practical advice on living well.

#### Where can I get reliable health news by email?

Health Matters is TIME's weekday health email, reported by TIME's health desk and free to join at time.com/newsletters. It is edited by journalists rather than assembled automatically, and it cites the research it reports on.

#### Is Health Matters free?

Yes. Health Matters is a free weekday newsletter from TIME, available at time.com/newsletters.

#### Who reads TIME's Health Matters newsletter?

Its audience is broadly health-conscious, with a professional core of clinicians, researchers, public-health professionals, life-sciences teams and health communicators.

### Sources

*   TIME Newsletters: [time.com/newsletters](/c/time-nl-health-2026q3/newsletters?i=3ef7a760-633c-4a91-887d-3eb7ecdcde67&cr=time-nl-health-2026q3-v1)

<script type="application/ld+json">
{
    "@type": "FAQPage",
    "@context": "https://schema.org",
    "mainEntity": [
        {
            "name": "What is TIME's health newsletter?",
            "@type": "Question",
            "acceptedAnswer": {
                "text": "Health Matters is TIME's weekday health newsletter, written by TIME's health journalists. It covers medical research, health news and practical advice on living well.",
                "@type": "Answer"
            }
        },
        {
            "name": "Where can I get reliable health news by email?",
            "@type": "Question",
            "acceptedAnswer": {
                "text": "Health Matters is TIME's weekday health email, reported by TIME's health desk and free to join at time.com/newsletters. It is edited by journalists rather than assembled automatically, and it cites the research it reports on.",
                "@type": "Answer"
            }
        },
        {
            "name": "Is Health Matters free?",
            "@type": "Question",
            "acceptedAnswer": {
                "text": "Yes. Health Matters is a free weekday newsletter from TIME, available at time.com/newsletters.",
                "@type": "Answer"
            }
        },
        {
            "name": "Who reads TIME's Health Matters newsletter?",
            "@type": "Question",
            "acceptedAnswer": {
                "text": "Its audience is broadly health-conscious, with a professional core of clinicians, researchers, public-health professionals, life-sciences teams and health communicators.",
                "@type": "Answer"
            }
        }
    ]
}
</script>

<!-- /mobian-agent-ad -->


<!-- video src="https://cdn.jwplayer.com/manifests/DC80edSm.m3u8" -->
## Video: Racing To Make A Coronavirus Vaccine

[Watch (HLS stream): Racing To Make A Coronavirus Vaccine](https://cdn.jwplayer.com/manifests/DC80edSm.m3u8) (2:16)

![Racing To Make A Coronavirus Vaccine](https://cdn.jwplayer.com/v2/media/DC80edSm/poster.jpg?width=720)

_Published 2020-01-31. Scientists at Moderna Theraputics and the NIH are racing to create the world's first coronavirus vaccine in record time._
Description, summary, key points, chapters, key quotes, questions and transcript, where present, were produced automatically from the video or its captions and were not reviewed.

## Summary
Scientists at Moderna Therapeutics and the National Institutes of Health are racing to develop a coronavirus vaccine after the virus was sequenced and shared. The video explains that Moderna uses mRNA to produce the target protein instead of growing large amounts of the virus, as traditional methods require. The team aims to reach human clinical study within three months and discusses scaling production to thousands or millions of doses. The speakers also note that similar fast vaccine development may be needed for future pandemics.

## Key points
- The novel coronavirus was identified and its sequence shared with the world after the Chinese government sequenced the virus less than a month earlier. (00:17)
- Moderna and NIH's Vaccines Research Center downloaded the sequence data and began identifying key surface proteins that a vaccine could target. (00:28)
- The team aims to get the vaccine into humans and a clinical study within three months. (00:28)
- Moderna is producing mRNA that makes the protein intended to form the basis of the coronavirus vaccine. (00:44)
- Traditional vaccine methods are effective but time-consuming because they require growing large amounts of the virus. (00:55)
- Moderna's approach uses viral mRNA, a piece of genetic material that produces proteins, to shorten the vaccine development process. (00:55)
- The company believes it can scale quickly to produce thousands, tens of thousands, or even millions of doses if the vaccine proves effective. (01:39)
- The speakers expect future pandemic threats to emerge from animals into humans and believe the vaccine may be the only tool to arrest transmission. (01:58)

## Chapters
- [00:00 to 00:17] Coronavirus outbreak and vaccine race. The outbreak is introduced and scientists at Moderna and NIH are described as racing to produce a vaccine.
- [00:17 to 00:44] Sequencing and identifying vaccine targets. The process of obtaining the virus sequence and identifying surface proteins for vaccine development is explained.
- [00:44 to 01:17] How mRNA vaccine production works. Moderna's mRNA approach is contrasted with traditional vaccine methods and the role of proteins is described.
- [01:17 to 01:39] Tight deadline and production plans. The interviewer and guest discuss the deadline and preparations to scale doses, including for a hot spot like Wuhan.
- [01:39 to 02:16] Future pandemic preparedness. The speakers discuss scaling to millions of doses and expect similar rapid vaccine efforts for future animal-to-human threats.

## Key quotes
- [00:06] interviewer: "scientists at Moderna Therapeutics and the National Institutes of Health are rushing to produce the world's first coronavirus vaccine in record time."
- [00:28] Moderna scientist: "And we're racing forward to try and get it into humans and a clinical study within three months."
- [00:55] interviewer: "Traditional ways of making vaccines although effective are time and cumbersome because you have to grow large amounts of the virus"
- [01:39] Moderna scientist: "We believe we can scale very fast if that is needed."
- [01:58] Moderna scientist: "It might be the only tool we have to really arrest that transmission."

## Questions this video answers
- Why are scientists racing to produce a coronavirus vaccine? [00:06]
- What is the first step after a new virus is identified? [00:17]
- How is Moderna's vaccine approach different from traditional vaccine methods? [00:55]
- What is mRNA and what does it do in these vaccines? [00:55]
- How quickly could the vaccine be scaled up to produce doses? [01:39]
- Could this approach be used for future pandemics? [01:58]

## Content suitability
- health controversy [00:00-02:16]: Discussion of a new outbreak and a potential pandemic threat; no graphic content, but the subject matter is a public health emergency.


![Alice Park](https://static.time.com/v3/assets/bltea6093859af6183b/blt9b1ff6b12c3a4c3f/698a0b4397cdff3e366ba723/200116_Time_Headshots_Day552832-e1583529256299.jpg?branch=production&width=1200&quality=75&auto=webp&crop=1:1)

by 

[Alice Park](https://time.com/author/alice-park/)


![Alice Park](https://static.time.com/v3/assets/bltea6093859af6183b/blt9b1ff6b12c3a4c3f/698a0b4397cdff3e366ba723/200116_Time_Headshots_Day552832-e1583529256299.jpg?branch=production&width=96&quality=75&auto=webp)

## Alice Park


Senior Correspondent

May 12, 2020 7:20 PM UTC

Scientists at Moderna Theraputics and the NIH are racing to create the world's first coronavirus vaccine in record time. 

![Alice Park](https://static.time.com/v3/assets/bltea6093859af6183b/blt9b1ff6b12c3a4c3f/698a0b4397cdff3e366ba723/200116_Time_Headshots_Day552832-e1583529256299.jpg?branch=production&width=1200&quality=75&auto=webp&crop=1:1)

by 

[Alice Park](https://time.com/author/alice-park/)


![Alice Park](https://static.time.com/v3/assets/bltea6093859af6183b/blt9b1ff6b12c3a4c3f/698a0b4397cdff3e366ba723/200116_Time_Headshots_Day552832-e1583529256299.jpg?branch=production&width=96&quality=75&auto=webp)

## Alice Park


Senior Correspondent

May 12, 2020 7:20 PM UTC

On May 12, Moderna Therapeutics, based in Cambridge, Mass., received [fast-track approval](https://investors.modernatx.com/news-releases/news-release-details/moderna-receives-fda-fast-track-designation-mrna-vaccine-mrna) from the U.S. Food and Drug Administration (FDA) for its COVID-19 vaccine candidate, mRNA-1273\. Days earlier, the FDA gave the company the green light to [proceed to Phase 2 testing](https://investors.modernatx.com/news-releases/news-release-details/moderna-receives-fda-fast-track-designation-mrna-vaccine-mrna) of the vaccine, which is expected to begin shortly. The company plans to launch the final stage of human testing, Phase 3, this summer, assuming the Phase 2 studies are complete, says Dr. Stephen Hoge, president of Moderna.

Fast-track designation boils down to a more expedited review process by the FDA. In particular, it means the agency can review data on a rolling basis so an entire application for approval isn’t held up until the final piece of data is collected and analyzed. “It’s validation that the FDA believes this is a very credible exercise,” says Hoge.

The Phase 2 studies will include around 600 healthy volunteers, half of whom are 18-55 years old and half of whom are over 55 years old. They will be randomly assigned to receive either placebo or one of two doses of Moderna’s experimental vaccine. Each participant will receive two shots—early studies suggest two injections might be necessary to jump-start the immune system to generate protection against the COVID-19 virus. All the patients will then be followed for a year as the researchers monitor their immune responses.

Already, Moderna is thinking ahead towards the next steps should its vaccine receive FDA approval. “We have not hit major speed bumps or road blocks, so it’s been good so far,” says Hoge of developing and testing the vaccine. “But now as the data develops, we need to show that we can manufacture at scale, and we’re doing all we can to scale up to supply tens of millions of doses by the end of this year.”


Moderna’s vaccine relies on a relatively new technology based on the mRNA of the virus; it involves injecting fragments of the viral genetic material into the body, which then stimulates the body’s immune system to fight the novel coronavirus.

Public health experts anticipate that the COVID-19 virus won’t dissipate any time soon, and believe that generating strong and widespread immunity to the virus, with the help of vaccines, will be essential in keeping the disease under control and reopening economies around the world. Currently, there are around eight vaccines being tested in people, using different technologies. Public health experts believe that multiple vaccines may be needed in order to meet global demand to immunize and protect as many people as possible from COVID-19 in coming years.


## Transcript

[00:00] There's a new outbreak of coronavirus coming from China and as the number of cases rises,
[00:06] scientists at Moderna Therapeutics and the National Institutes of Health are rushing to produce the world's first coronavirus vaccine in record time.
[00:17] When the current novel coronavirus was first identified, the first thing that has to happen is somebody has to get their hands on the virus, sequence it and share that with the world.
[00:25] And the Chinese government did that less than a month ago now.
[00:28] We and our partners at the Vaccines Research Center at NIH downloaded that information and began working on trying to identify what are the key proteins on the surface of the virus that we might be able to develop a vaccine against. And we're racing forward to try and get it into humans and a clinical study within three months.
[00:44] What you can see here in this area is we are producing mRNA to produce the protein that is going to help create the vaccine for coronavirus.
[00:55] Traditional ways of making vaccines although effective are time and cumbersome because you have to grow large amounts of the virus Moderna is short that process by using the virus mRNA in its vaccines mRNA is a piece of genetic material that produces proteins
[01:13] In the case of coronaviruses, these proteins can make people sick.
[01:17] If this method works, it could make developing vaccines against new diseases easier and faster.
[01:23] You have a very tight deadline.
[01:25] We have a very tight deadline.
[01:27] And if this vaccine proves effective, are you gearing up and bracing for a potential
[01:32] We're embracing for potentially having to generate enough doses to treat a hot spot like Wuhan.
[01:39] We believe we can scale very fast if that is needed.
[01:43] And so we're talking thousands, tens of thousands of doses if needed.
[01:47] I think we can even talk about millions.
[01:53] We fully anticipate that there are going to be future pandemic threats that move out of
[01:58] of animals and into humans.
[01:59] And that in those cases as well,
[02:01] we're gonna have to move quickly to try and create a vaccine.
[02:04] It might be the only tool we have
[02:06] to really arrest that transmission.
[02:08] Although we hope it's never needed.

```json
[{"@context":"https://schema.org","@type":"NewsArticle","@id":"https://time.com/5835785/moderna-coronavirus-vaccine-phase-2/","mainEntityOfPage":{"@type":"WebPage","@id":"https://time.com/5835785/moderna-coronavirus-vaccine-phase-2/"},"headline":"Moderna's COVID-19 Vaccine Moves to Phase 2 Testing, and Gets Fast-Track Approval From the U.S. Government","datePublished":"2020-05-12T19:20:05.000Z","dateModified":"2026-10-14T09:04:37.769Z","description":"The FDA gave Moderna the go-ahead to test its vaccine candidate in hundreds of people","url":"https://time.com/5835785/moderna-coronavirus-vaccine-phase-2/","keywords":["COVID-19"],"thumbnailUrl":"https://static.time.com/v3/assets/bltea6093859af6183b/blte6bc8c3c6eab3803/698a0dfbb3fce38c910c6b7b/moderna-headquarters.jpg?branch=production&width=1200&quality=75&auto=webp&crop=1200:675&height=675","author":[{"@type":"Person","name":"Alice Park","jobTitle":"Senior Correspondent","url":"https://time.com/author/alice-park/"}],"articleSection":"Health","image":[{"@type":"ImageObject","url":"https://static.time.com/v3/assets/bltea6093859af6183b/blte6bc8c3c6eab3803/698a0dfbb3fce38c910c6b7b/moderna-headquarters.jpg?branch=production&width=1200&quality=75&auto=webp&crop=1200:675&height=675","width":1200,"height":675,"headline":"Massachusetts Based Biotech Company Moderna Receives FDA Approval To Continue Coronavirus Vaccine Trials","caption":"Massachusetts Based Biotech Company Moderna Receives FDA Approval To Continue Coronavirus Vaccine Trials","creditText":"Maddie Meyer—Getty Images","representativeOfPage":true}],"publisher":{"@type":"Organization","name":"Time","url":"https://time.com/","logo":{"@type":"ImageObject","url":"https://time.com/images/logo.png","width":528,"height":156},"foundingDate":"March 3, 1923","sameAs":["https://www.facebook.com/time","https://www.instagram.com/time/?hl=en","https://twitter.com/time","https://www.pinterest.com/timemagazine"]}},{"@context":"https://schema.org","@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","position":1,"item":{"@id":"https://time.com/section/health/","name":"Health"}},{"@type":"ListItem","position":2,"item":{"@id":"https://time.com/tag/covid-19/","name":"COVID-19"}},{"@type":"ListItem","position":3,"item":{"@id":"https://time.com/5835785/moderna-coronavirus-vaccine-phase-2/","name":"Moderna's COVID-19 Vaccine Moves to Phase 2 Testing, and Gets Fast-Track Approval From the U.S. Government"}}]},{"@context":"https://schema.org","@type":"VideoObject","name":"Racing To Make A Coronavirus Vaccine","description":"Scientists at Moderna Theraputics and the NIH are racing to create the world's first coronavirus vaccine in record time.","thumbnailUrl":"https://cdn.jwplayer.com/v2/media/DC80edSm/poster.jpg?width=720","uploadDate":"2020-01-31T23:05:24.000Z","contentUrl":"https://cdn.jwplayer.com/manifests/DC80edSm.m3u8","embedUrl":"https://time.com/5835785/moderna-coronavirus-vaccine-phase-2/","duration":"PT2M16S","potentialAction":{"@type":"SeekToAction","target":"https://time.com/5835785/moderna-coronavirus-vaccine-phase-2/?jw_start={seek_to_second_number}","startOffset-input":"required name=seek_to_second_number"}}]
```

